Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials ...

Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by ...

Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new investor the Retinal ...

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –-- ...

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 - -- Expects to initiate global Phase 1/2 MAD clinical study ...

Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...

DelveInsight's Persistent Corneal Edema Market Insights report includes a comprehensive understanding of current treatment practices, persistent corneal edema emerging drugs, market share of ...

Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new investor the Retinal Degeneration Fund, and supported by existing investorsFunds will advance laru-zova ...

LoQus23 Therapeutics Ltd ("LoQus23"), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington's Disease ...

Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.

With a progressive disease like FSHD, the loss of abilities and independence has an unpredictable timeline, says columnist.

The firm at the JP Morgan Healthcare Conference additionally expects a regulatory decision on its gene therapy RGX-121 for Hunter syndrome next month.